Myocardial Energetics as a Therapeutic Target

Abstract

Alterations in myocardial energetics are increasingly recognized as central to the pathogenesis of heart failure and other cardiac diseases. This review elucidates the mechanistic underpinnings of myocardial energy metabolism, explores the clinical and epidemiological implications of energetic dysfunction, and critically appraises current and emerging therapeutic strategies targeting myocardial energetics. Recent advances highlight the translational potential of metabolic modulation for improved cardiac outcomes, supporting a paradigm shift in the management of heart failure and related conditions.

Introduction

The heart is a metabolically demanding organ, consuming vast amounts of ATP to sustain continuous contractile activity. Myocardial energetics encompasses the intricate processes of substrate utilization, ATP production, and energy transfer within cardiomyocytes. Disruption of these processes contributes to the progression of heart failure, ischemic heart disease, and cardiomyopathies. Targeting myocardial energetics offers a novel avenue for therapeutic intervention, with growing evidence suggesting that metabolic modulation may improve both symptoms and clinical outcomes in select patient populations.

Epidemiology / Disease Burden

Heart failure affects over 26 million individuals worldwide, with significant morbidity, mortality, and healthcare costs. Energetic impairment is a universal feature of both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The burden of ischemic heart disease, diabetes, obesity, and hypertension conditions closely linked to metabolic dysregulation further amplifies the clinical relevance of myocardial energetics. Recent epidemiological studies underscore the association between impaired myocardial energy metabolism and adverse cardiovascular outcomes, independent of traditional risk factors.

Pathophysiology

In healthy myocardium, energy production relies predominantly on mitochondrial oxidative phosphorylation, utilizing fatty acids, glucose, lactate, and ketone bodies as substrates. In disease states, there is a maladaptive shift in substrate preference, mitochondrial dysfunction, impaired ATP synthesis, and accumulation of metabolic intermediates. Heart failure is characterized by decreased myocardial creatine and phosphocreatine reserves, reduced ATP turnover, and impaired energy transfer from mitochondria to contractile apparatus. These alterations contribute to contractile dysfunction, arrhythmogenesis, and progression of myocardial remodeling.

Risk Factors

Risk factors for myocardial energetic impairment encompass both systemic and cardiac-specific domains. Diabetes mellitus, metabolic syndrome, obesity, and hypertension promote substrate overload, insulin resistance, and lipotoxicity. Coronary artery disease and chronic ischemia disrupt oxygen delivery and mitochondrial function. Genetic and acquired cardiomyopathies may directly affect mitochondrial biogenesis and ATP synthesis. Age-related changes further exacerbate energetic inefficiency, increasing susceptibility to heart failure and arrhythmias.

Clinical Features

Patients with myocardial energetic dysfunction typically present with features of heart failure exertional dyspnea, fatigue, exercise intolerance, and reduced cardiac output. Advanced energetic deficits manifest as low-output syndromes, poor contractile reserve, and arrhythmias. Infiltrative and metabolic cardiomyopathies may present with atypical features, including conduction disturbances and skeletal muscle involvement. Biomarkers such as elevated natriuretic peptides reflect hemodynamic stress but do not directly quantify energetic status, underscoring the need for advanced diagnostic modalities.

Diagnosis

Assessment of myocardial energetics in clinical practice remains challenging. Non-invasive techniques such as phosphorus-31 magnetic resonance spectroscopy (31P-MRS) allow quantification of myocardial phosphocreatine-to-ATP ratios, serving as a surrogate for energetic reserve. Positron emission tomography (PET) can assess substrate utilization and mitochondrial function. Echocardiographic strain imaging and cardiac MRI delineate contractile inefficiency secondary to energetic impairment. Ongoing research seeks to validate novel circulating biomarkers and imaging modalities for routine clinical use.

Treatment & Management

Current management of myocardial energetic dysfunction relies on optimizing underlying cardiovascular risk factors, controlling comorbidities, and implementing guideline-directed heart failure therapies. Beta-blockers, ACE inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and mineralocorticoid receptor antagonists indirectly improve myocardial energetics by reducing workload and neurohormonal activation. Lifestyle interventions such as exercise training and dietary modification may enhance mitochondrial efficiency and substrate utilization. Metabolic modulators, including trimetazidine and perhexiline, directly target substrate selection and ATP production, offering symptomatic improvement in select populations.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of novel therapies targeting myocardial metabolism. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for diabetes, have demonstrated robust cardiovascular benefits, possibly via enhanced cardiac energetics and improved ketone utilization. Agents targeting mitochondrial dynamics, AMP-activated protein kinase (AMPK) activation, and peroxisome proliferator-activated receptor (PPAR) modulation are under investigation. Gene and stem cell therapies aiming to restore mitochondrial function and ATP production represent promising, though experimental, avenues.

Guideline Recommendations

Contemporary heart failure management guidelines emphasize a comprehensive approach, integrating pharmacologic and non-pharmacologic interventions to optimize cardiac performance and metabolic health. While guideline-directed therapies form the cornerstone of management, the incorporation of metabolic modulators is currently limited to select patient subsets. Ongoing trials and evolving evidence are likely to inform future recommendations regarding the routine use of agents specifically targeting myocardial energetics, particularly in patients with refractory symptoms or metabolic comorbidities.

Conclusion

Myocardial energetics represents a critical and modifiable determinant of cardiac function, with broad implications for the diagnosis, management, and prognosis of heart failure and related disorders. Advances in our understanding of myocardial metabolism have catalyzed the development of novel therapeutic strategies, offering hope for improved outcomes in a traditionally challenging patient population. Continued research is essential to refine diagnostic tools, validate emerging therapies, and integrate metabolic modulation into precision cardiovascular care.